Development Roadmap
From candidates to clinic.
Our roadmap advances two programs — a lead endometriosis candidate (ESB-001), an RNA-based, lesion-selective therapeutic, and an earlier-stage oncology program — through the studies needed to support future clinical filings, with clear go/no-go criteria at each phase.
ESB-001EndometriosisUndisclosed
Our lead program is an RNA-based, lesion-selective therapeutic designed to act on the local drivers of endometriotic lesions while sparing systemic endocrine function — now advancing through lead development toward translational studies.
ESB-002Women's cancers (oncology)Undisclosed
An earlier-stage program extending Esma Bio's precision platform toward women's cancers, currently in discovery. Program details are shared with qualified partners under CDA.
ESB-001Endometriosis
Target: Undisclosed
ESB-001
Our lead program is an RNA-based, lesion-selective therapeutic designed to act on the local drivers of endometriotic lesions while sparing systemic endocrine function — now advancing through lead development toward translational studies.
ESB-002Women's cancers (oncology)
Target: Undisclosed
ESB-002
An earlier-stage program extending Esma Bio's precision platform toward women's cancers, currently in discovery. Program details are shared with qualified partners under CDA.
Molecular targets remain undisclosed. Confidential study designs and regulatory plans are shared with qualified investors under CDA.